MKI67 and breast cancer: Most recently a significant study identified that the prognostic information provided by ‘IHC4’ (ER, PR, HER2 and Ki-67) was at least equivalent to Oncotype Dx (Cuzick et al, 2009) and highlights the relevance of these readily available routine pathology markers in the clinical management of breast cancer.